Company Encyclopedia
View More
name
LEPU BIO-B
02157.HK
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of first-in class and best-in-class drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive. In addition, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin’s lymphoma; CMG901 CLDN18.2-targeted ADC for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC for treating advanced or metastatic solid tumors.
1.305 T
02157.HKMarket value -Rank by Market Cap -/-

Financial Score

21/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking21/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-21.35%E
    • Profit Margin-25.30%E
    • Gross Margin94.12%A
  • Growth ScoreB
    • Revenue YoY242.06%A
    • Net Profit YoY-144.37%E
    • Total Assets YoY-1.45%D
    • Net Assets YoY-19.62%E
  • Cash ScoreC
    • Cash Flow Margin-395.29%D
    • OCF YoY242.06%A
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreD
    • Gearing Ratio69.86%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    LEPU BIO-B: Yang Ming resigns as supervisor

    According to the Zhitong Finance APP, LEPU BIO-B announced that Yang Ming has resigned from his position as supervisor of the company due to retirement. After the resignation takes effect, Yang Ming will no longer hold any position in the company

    Zhitong·
    HK
    02157
    +5.23%
    Zhitong·
    HK
    02157
    +5.23%

    LEPU BIO-B: Meiyouheng® (Injection Vabecotuzumab) for the treatment of R/M NPC approved for market launch

    LEPU BIO-B announced that its self-developed EGFR-targeted antibody drug Meiyouheng® (injection of Vebekotamab) has been approved by the National Medical Products Administration for marketing in China. This drug is used for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) and is the first EGFR-targeted ADC approved in the country, marking an important milestone for the company. The company plans to further expand the indications of this drug based on this approval to enhance its commercial value

    Zhitong·
    HK
    02157
    +5.23%
    Zhitong·
    HK
    02157
    +5.23%

    Cathay Securities and Haitong Securities: Initiates "Buy" rating on LEPU BIO-B, MRG003 expected to be approved domestically soon

    CITIC Securities has initiated coverage on LEPU BIO-B with a rating of "Buy" and a target price of RMB 9.55 / HKD 10.38. It is expected that the operating revenues for 2025-2027 will be RMB 853 million / RMB 1.204 billion / RMB 1.665 billion, respectively. The company's MRG003 is about to be approved and has established multiple oncology product pipelines, covering immunotherapy, ADC targeted therapy, and oncolytic virus drugs. MRG003 is expected to receive CDE priority review qualification in 2024 and submit NDA for review in 2025

    Zhitong·
    HK
    02157
    +5.23%
    Zhitong·
    HK
    02157
    +5.23%

    Breakthrough! LEPU BIO has completed the enrollment of the first patient in the Phase II clinical trial for hepatocellular carcinoma

    LEPU BIO's targeted GPC3 antibody-drug conjugate MRG006A has successfully completed the enrollment of its first patient in a Phase II clinical study for advanced hepatocellular carcinoma, becoming the world's first GPC3 ADC drug to enter Phase II. This drug precisely targets GPC3-positive tumor cells to release toxins for targeted killing, demonstrating significant innovative value

    Zhitong·
    HK
    02157
    +5.23%
    Zhitong·
    HK
    02157
    +5.23%

    Understanding the Market | LEPU BIO-B rose over 4% in early trading as MRG003 is expected to be included in breakthrough therapy designation targeting refractory nasopharyngeal carcinoma

    LEPU BIO-B rose over 4% in early trading, as of the time of writing, it increased by 4.11%, priced at HKD 7.34, with a transaction volume of HKD 30.16 million. In terms of news, on September 19, the CDE official website announced that LEPU BIO's EGFR-targeted ADC drug MRG003 is proposed to be included in the breakthrough therapy designation, indicated for use in combination with Pembrilizumab (PD-1 monoclonal antibody) for the treatment of recurrent or metastatic nasopharyngeal carcinoma in patients who have previously failed platinum-based and PD-1/PD-L1 inhibitor treatments. It is reported that MRG003 is currently the leading EGFR ADC drug in global development progress, having previously received breakthrough therapy designation and priority review qualification from the CDE, as well as orphan drug status, fast track designation, and breakthrough therapy designation from the FDA. In September 2024, LEPU BIO initially submitted a marketing application for this drug for nasopharyngeal carcinoma, but later withdrew it voluntarily due to the need for supplementary materials, and resubmitted it in March this year. It is currently included in the priority review process for monotherapy in specific recurrent/metastatic nasopharyngeal carcinoma patients

    Zhitong·
    HK
    02157
    +5.23%
    Zhitong·
    HK
    02157
    +5.23%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer